Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema 2.4 mg/2.4 mg) Once Weekly Versus Placebo in Participants With Obesity

NCT06780449 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT06780449
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06780449 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema 2.4 mg/2.4 mg) Once Weekly Versus Placebo in Participants With Obesity
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 10, 2025
Completion date
October 31, 2028
Enrollment
400 (estimated)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

obesity